| Outcome Measures: |
Primary: Change From Baseline in Hemoglobin Level at Week 4, 4 weeks|Number of Participants With Composite Events of Death, Myocardial Infarction and Cerebrovascular Accident, Serious Events of Unstable Angina, Transient Ischemic Attack, Arrythmia and Congestive Heart Failure, Peripheral Thrombo-embolic Events, 16 Weeks|Number of Participants With Composite Events of Transfusion-related Adverse Experiences, 16 Weeks|Number of of Participants With Composite Events of Injection Site Reactions, 16 Weeks|Number of Participants With Hypertension, Seizure, and Pure Red Cell Aplasia, 16 Weeks|Number of Participants With Confirmed, Treatment Emergent Antibodies to MK2578, 16 Weeks | Secondary: Hemoglobin Concentration After Treatment With MK2578, Weeks 1-10 and Week 12|Change From Baseline in Hemoglobin Level, Weeks 1-3, 5-10, and Week 12|Number of Participants Who Were Responders, Responder was defined as a participant achieving (pre-transfusion) an increase from baseline hemoglobin of greater than or equal to 1 g/dL and a hemoglobin concentration of greater than or equal to 11 g/dL., Each week up to 12 weeks
|
